June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Posterior Sub-Tenon Triamcinolone Acetonide Injection For Treatment of Intraocular Inflammation and Macular Edema Associated with Uveitis
Author Affiliations & Notes
  • Maria Soledad Ormaechea
    Hospital Universitario Austral, Buenos Aires, Argentina
    Hospital de Clinicas Jose de San Martin, Buenos Aires, Argentina
  • Mariana Ingolotti
    Hospital Universitario Austral, Buenos Aires, Argentina
  • Cristobal A Couto
    Hospital de Clinicas Jose de San Martin, Buenos Aires, Argentina
  • Mario Joaquin Saravia
    Hospital Universitario Austral, Buenos Aires, Argentina
  • Ariel Shlaen
    Hospital Universitario Austral, Buenos Aires, Argentina
    Hospital de Clinicas Jose de San Martin, Buenos Aires, Argentina
  • Footnotes
    Commercial Relationships   Maria Ormaechea, None; Mariana Ingolotti, None; Cristobal Couto, None; Mario Saravia, None; Ariel Shlaen, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 522. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Maria Soledad Ormaechea, Mariana Ingolotti, Cristobal A Couto, Mario Joaquin Saravia, Ariel Shlaen; Posterior Sub-Tenon Triamcinolone Acetonide Injection For Treatment of Intraocular Inflammation and Macular Edema Associated with Uveitis. Invest. Ophthalmol. Vis. Sci. 2017;58(8):522.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To assess the effectiveness of posterior sub-Tenon (PST) triamcinolone acetonide injection in the treatment of intraocular inflammation and macular edema associated with uveitis.

Methods : Clinical data from patients with diagnosis of uveitis who were treated with PST triamcinolone acetonide injection at the uveitis department from Hospital Universitario Austral was reviewed. Information collected consisted in age, gender, anatomic and clinical course classification according to the SUN study group criteria. Best corrected visual acuity (BCVA) before and 1 and 3 months after injection, anterior chamber inflammation grade, vitreous haze, posterior segment inflammation signs (retinal vasculitis, papillitis, choroidal thickening at EDI OCT, and choroiditis) before and 1, 3 and 6 months after the injection were reviewed. When macular edema was identified, central retinal thickness (CRT) before and at 1 month after injection was recorded. Development of complications such as ocular hypertension and cataract were consigned.

Results : One hundred and one eyes from 70 patients (26 males y 44 females) were found. Average age was of 40,56 ± 18,35 years (women: 40,52 ± 18,35 años, men: 40,62 ± 18,71 years). A total of 242 PST injections were performed. Macular edema was the main indication in 71 injections, intraocular inflammation was the main indication in 183 injections, while 19 injections were performed for both reasons. BCVA in macular edema before injection was less than 20/60 in 24 procedures (36,36%), 20/60 to less than 20/40 in 18 procedures (27,27%), and 20/40 or better in 24 procedures (36,36%). BCVA at 1 month of follow up after injection was less than 20/60 in 18 procedures (27,27%), 20/60 to less than 20/40 in 7 procedures (10,6%), and 20/40 or better en 41 procedures (62,12%) (chi square = 10.14, P<0.01). Average CRT before injection was 388,40 ± 94,61 microns, and average central retinal thickness 1 month after injection was 266,11 ± 62,10 microns (t student test for paired samples: 6,629, P < 0.001).

Conclusions : PST injection was effective for improving best corrected visual acuity and decreasing CRT in macular edema. It was also effective in improving intraocular inflammation parameters in uveitis.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×